There are no known interactions between Leqvio and other medicines. But it is still important for your health care provider to be aware of all the prescription and over-the-counter (OTC) medicines, vitamins/minerals, herbal products, and other supplements you take or have recently taken. ...
Leqvio is an injectable prescription medicine indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to red...
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a ...
As previously announced, a supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis is under review by theU.S. Food and Drug Administration(FDA), with an action date ofOctober 8, 2023under the Prescription Drug User Fee Act (PDUFA). P...
Apart from cancer, orphan diseases too have an urgent need for novel and effective remedies which is slowly being fulfilled by the chemically synthesized siRNA therapeutics. Till date five siRNA-based drugs namely Patisiran, Givlaari, Oxlumo™, Leqvio and Amvuttra have been approved by USFDA, ...
(lumasiran), and Leqvio®(inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage dev...
Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of ...